Investor Relations

Investing in Lucid Diagnostics is investing in innovation that has the potential to impact and even transform healthcare.

Company Overview

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

Stock Information
Market Cap
Stock Information

Latest News & Updates

Jun 12, 2024

Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK, June 12, 2024 /PRNewswire/ -- Lucid Diagnostics...

May 13, 2024

Quarterly EsoGuard® test volume increased 10 percent Strengthened balance sheet following completion of $29.8 million Series B Preferred Stock Offering MolDX pre-submission meeting scheduled for...

May 9, 2024

EsophaCap device recalled due to recent publication of serious device failures Lucid Diagnostics' EsoCheck® unaffected by recall and remains the gold standard for non-endoscopic cell collection...